|1.||Fujii, Yoshitaka: 16 articles (12/2011 - 03/2002)|
|2.||Miller, Donald R: 11 articles (12/2012 - 12/2012)|
|3.||Fujii, Y: 10 articles (06/2001 - 01/2000)|
|4.||Tanaka, Hiroyoshi: 8 articles (01/2006 - 05/2002)|
|5.||Tanaka, H: 8 articles (06/2001 - 01/2000)|
|6.||Cooper, William: 4 articles (09/2015 - 01/2015)|
|7.||O'Boyle, Erin: 4 articles (09/2015 - 01/2015)|
|8.||Boccia, Ralph: 4 articles (09/2015 - 01/2015)|
|9.||Ernberg, Malin: 4 articles (01/2015 - 02/2003)|
|10.||Gan, Tong J: 4 articles (11/2009 - 01/2005)|
08/01/2012 - "The efficacy of granisetron was measured on each day using the complete regression(no vomiting and no rescue medication; CR)rate. "
09/01/1997 - "The percentage of emesis-free patients was significantly greater in the 5- to 20-microg/kg granisetron groups than in the control and 2-microg/kg granisetron groups (18%, 23%, 68%, 78%, and 75% of patients receiving saline or granisetron 2 microg/kg, 5 microg/kg, 10 microg/kg, and 20 microg/kg, respectively). "
08/01/2003 - "Additionally, incremental doses of granisetron (up to 9 mg) have been shown to be effective and well tolerated in patients with refractory emesis. "
01/01/1994 - "The efficacy of Granisetron, a new and selective 5HT3-receptor-antagonist in the treatment of cytostatic induced emesis, was tested in the department of gynaecology and obstetrics of the University of Essen on 77 patients. "
11/15/1995 - "However, the addition of corticosteroid to orally administered granisetron improved the control of delayed emesis. "
04/01/1995 - "Granisetron proved significantly effective in preventing nausea, as 75% of granisetron-administered patients experienced either only slight nausea or none at all, against only 22.5% in the non-granisetron group. "
12/01/1998 - "The study demonstrated that Granisetron is more active than placebo in controlling nausea (3 cases vs 4), and retching (2 vs 6). "
09/01/1997 - "Granisetron doses of 5 microg/kg or larger were also superior to the saline and 2-microg/kg granisetron treatment for the prevention of nausea over the 24-h study period (nausea visual analog scales 24 h after surgery: 49, 41, 18, 16, and 14 mm in the control and granisetron 2 microg/kg, 5 microg/kg, 10 microg/kg, and 20 microg/kg groups, respectively). "
05/01/1995 - "Granisetron at both doses also was superior to the control for the prevention of nausea over the 24-h study period (nausea visual analog scales at 24-h postsurgery: 49 mm, 17 mm, and 18 mm in the control, granisetron 20 micrograms/kg, and granisetron 40 micrograms/kg groups, respectively). "
04/01/2014 - "On the basis of the results of multivariate analysis, young age, female gender, and the use of granisetron were significant risk factors for delayed nausea. "
|3.||Postoperative Nausea and Vomiting (PONV)
02/01/1998 - "Granisetron is highly effective for reducing the incidence of PONV in female patients undergoing breast surgery. "
07/01/1998 - "This study was designed to evaluate the efficacy of granisetron administered orally for preventing PONV in female patients undergoing major gynaecological surgery. "
01/01/2012 - "Efficacy of Generic Granisetron vs Kytril® for PONV in Major Gynecological Operations: A Randomized, Double-blind Clinical Trial."
03/01/2001 - "Preoperative oral granisetron, in doses of more than 2 mg, is effective for the prevention of postoperative nausea and vomiting in women undergoing general anaesthesia for breast surgery."
09/01/1998 - "We conclude that preoperative oral granisetron, in doses more than 40 micrograms kg-1, was effective for the prevention of postoperative vomiting in children."
07/01/1995 - "The safety and efficacy of the new 5HT-3 antagonist granisetron as an antiemetic in children with cancer was evaluated in 40 children at a single dose of 40 micrograms/kg. No adverse affects attributable to the granisetron were noted. "
10/01/2005 - "To compare the efficacy of anti-emetic and prophylactic effects of 1 milligram (mg) versus 3 mg granisetron in cancer patients. "
12/01/1993 - "[Antiemetic efficacy of granisetron in pediatric cancer treatment--(2). "
10/01/2007 - "Few trials have been conducted to determine the optimal effective dose of granisetron in children with cancer. "
08/01/1999 - "This multi-center open study was conducted to study the efficacy, safety and usefulness of granisetron in children with cancer. "
01/01/1999 - "Oral granisetron for strabismus surgery in children."
09/01/1999 - "Preoperative oral granisetron, in doses more than 40 microg/kg, is effective for preventing vomiting after strabismus surgery in children."
09/01/1999 - "To evaluate the efficacy of oral granisetron for the prevention of postoperative vomiting in children undergoing strabismus surgery. "
01/01/1999 - "To determine the efficacy of oral granisetron in preventing postoperative vomiting (POV) following strabismus repair in children. "
09/01/1999 - "Preoperative oral granisetron for the prevention of vomiting after strabismus surgery in children."
|6.||Serotonin (5 Hydroxytryptamine)
|10.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|1.||Drug Therapy (Chemotherapy)
|4.||Gynecologic Surgical Procedures (Gynecologic Surgery)